Reduced Dosing Option Approved for Orfadin in HT-1

Orfadin is a competitive 4-hydroxyphenyl-pyruvate dioxygenase inhibitor
Orfadin is a competitive 4-hydroxyphenyl-pyruvate dioxygenase inhibitor

The Food and Drug Administration (FDA) has approved a reduced dosing frequency for Orfadin (nitisinone; Sobi) in the treatment of hereditary tyrosinemia type 1 (HT-1). Orfadin can now be dosed once daily, rather than twice daily, in patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone.

The approval of the once-daily dosing option was based on a clinical study that compared a 4-week once-daily regimen to a 4-week twice daily regimen; both regimens showed comparable blood levels of nitisinone in the 16 HT-1 patients treated. 

Orfadin is a competitive 4-hydroxyphenyl-pyruvate dioxygenase inhibitor that works by blocking the normal catabolism of tyrosine, thus preventing the accumulation of catabolic intermediates maleylacetoacetate and fumarylacetoacetate. In patients with HT-1, these intermediates are converted to toxic metabolites that are responsible for hepatic and renal toxicity.

Related Articles

Orfadin is available in both capsule (2mg, 5mg, 10mg, 20mg) and oral suspension (4mg/mL) formulations.

For more information visit Orfadin.com.